Recent Updates
Recently added Catalysts

Influenza vaccine GSK2186877A

Phase 3

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jul 31, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
Double-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment971
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00772889Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the ElderlyPHASE3 COMPLETED 971Oct 9, 2008Dec 15, 2009Jul 31, 201829 United States, Belgium +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Day 0-6

Grade 3 ecchymosis, redness and swelling were ≥ 100 millimeters (mm) and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was \>20 mm for ecchymosis, redness and swelling.

Duration of Solicited Local AEs
Day 0-6

Duration was defined as number of days with any grade of local symptoms.

Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Day 0-6

Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to the study vaccination, grade 3 was defined as a general symptom that prevented normal activity. Related arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever were defined as general symptoms assessed by the investigator as causally related to the study vaccination.

Duration of Solicited General AEs
Day 0-6

Duration was defined as number of days with any grade of general symptoms.

Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Day 0-20

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade. Grade 3 was defined as an unsolicited symptom that prevented normal activity. Related was an event assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) During Day 0 to Day 20
Day 0-20

For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases From Day 0 to Day 20
Day 0-20

AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 0 to Day 20
Day 0-20

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.

Secondary Endpoints
Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) Between Day 21 and Day 179
Day 21-179
Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases Between Day 21 and Day 364
Day 21-364.
Haemagglutination Inhibition (HI) Antibody Titers
Day 0-21
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
New generation influenza vaccine GSK2186877A GroupEXPERIMENTALSubjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
Fluarix elderly GroupACTIVE_COMPARATORSubjects aged ≥66 years received one dose of Fluarix vaccine.
Fluarix young GroupACTIVE_COMPARATORSubjects aged 19-43 years received one dose of Fluarix vaccine.
Interventions
NameTypeDescription
Influenza vaccine GSK2186877ABIOLOGICALOne intramuscularly injection at Day 0
GSK Biologicals' Fluarix™BIOLOGICALOne intramuscularly injection at Day 0
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites29

Inclusion Criteria: * A male or female subject previously enrolled in study 109821 (NCT 00529516) in the \>= 65 years and 18-41 years of age groups and having received the study vaccine. * Subjects of whom the investigator believes that they can and will comply with the requirements of the protocol...

Countries:United StatesBelgiumGermanyNorway
Unlock Eligibility Criteria